BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20220101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230822
DTEND;VALUE=DATE:20230825
DTSTAMP:20260516T065812
CREATED:20230406T130638Z
LAST-MODIFIED:20230406T130725Z
UID:37042-1692662400-1692921599@www.pharmajournalist.com
SUMMARY:2nd ADC Linker & Conjugation 2023
DESCRIPTION:Investments in linker and conjugation technologies have become the single-biggest area of investments within the ADC field\, showing how they are being used as key levers for ADC drug developers to pull to create ADCs with a widened therapeutic index. \nThe inaugural ADC Linker & Conjugation Summit has been specifically designed to drive innovations in linker and conjugation chemistries that result in stable ADCs\, with low aggregation and controlled release\, which can be replicated at scale. \nSee the complete event guide here. \nHere’s a snapshot of our speaker faculty\, including expert industry leaders such as: \n\nSayumi Yamazoe\, Senior Principal Scientist\, Bristol Myers Squibb\nRomas Kudirka\, Director\, Chemistry & Bioconjugation\, Bolt Biotherapeutics\nDonglu Zhang\, Senior Fellow\, Genentech\nPaul Song\, Chief Scientific Officer\, Genequantum\nPatrick Higgs\, Principal Scientist\, Chemistry\, Iksuda\nNoah Bindman\, Principal Scientist\, Seagen\nMarc-André Kasper\, Director\, Chemistry & Early Discovery\, Tubulis\nPaul Sauter\, Director\, Chemistry\, VERAXA\n\n…and many more!\nFind the full list of speakers and session details here. \nBe part of the first industry-dedicated meeting for professionals just like you\, interested in learning about developments in the field of ADC linkers and conjugations\, and overcoming common challenges with stability.
URL:https://www.pharmajournalist.com/event/2nd-adc-linker-conjugation-2023/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:adc@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230823
DTEND;VALUE=DATE:20230825
DTSTAMP:20260516T065812
CREATED:20230608T112726Z
LAST-MODIFIED:20230608T112726Z
UID:37312-1692748800-1692921599@www.pharmajournalist.com
SUMMARY:RNA Assay Development & Screening Summit
DESCRIPTION:Bringing together technical experts from biopharma and academia\, the brand-new RNA Assay Development & Screening Summit has been curated to support in-house assay development and screening strategies to find new RNA targets\, and ultimately determine biological effect in a manner that supports progression from early discovery to drug candidate. \nDeveloped in collaboration with experts in the field\, join 60+ key opinion leaders from the likes of Arrakis Therapeutics\, Expansion Therapeutics and NextRNA at the first technical RNA meeting of its kind! \nCome away with actionable insights after deep diving into the latest technical expertise and explore learnings from data-driven case studies. \nDon’t miss this unique opportunity expand and validate your assay and screening strategies and accelerate the path to the clinic! Learn more – https://ter.li/8fsu01
URL:https://www.pharmajournalist.com/event/rna-assay-development-screening-summit/
LOCATION:The Bostonian Boston\, 26 NORTH STREET\, BOSTON\, MA\, 02109\, United States
ORGANIZER;CN="Hanson Wade Group":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR